Agilon Health, Inc. (AGL) Securities Class Action Lawsuit Filed [January 6, 2026]

Introduction to Agilon Health, Inc. (AGL) Securities Class Action Lawsuit

A securities fraud class action has been filed against Agilon Health, Inc. (NYSE: AGL) on behalf of investors who traded the Company's (common stock) between February 26, 2025 and August 4, 2025. Investors allege the Company touted 2025 financial guidance and the immediate benefits of "strategic actions" while understating worsening industry headwinds and near-term risks, including higher-than-expected Medicare Advantage utilization and medical costs. The truth surfaced on August 4, 2025, when Agilon announced disappointing results, an abrupt guidance withdrawal, and disclosed that expected benefits would not materialize until 2026, alongside the CEO's departure. The complaint ties these reversals to prior statements that the Company was "on track" and that strategy changes would drive 2025 performance, inflating the effectiveness of its physician partnership business model. In the aftermath, shareholders absorbed steep losses, in a single trading day.

Agilon Health, Inc. (AGL) Securities Lawsuit Case Details

Case Name: Vandersluis v. Agilon Health, Inc. et al.

Case No.: 1:25-cv-07167

Jurisdiction: U.S. District Court, Eastern District of New York

Filed on: December 31, 2025

Agilon Health, Inc. (AGL) Company Profile

Agilon describes itself as the "trusted partner empowering physicians to transform health care in our communities." The Company serves Medicare Advantage Members (Medicare Advantage beneficiaries) and ACO Model Members, within its value-based care physician partnership platform in the healthcare services industry, and its common stock trades on the NYSE (NYSE: AGL) under the ticker AGL.

Agilon Health, Inc. (AGL) Securities Lawsuit Class Period

February 26, 2025-August 4, 2025, inclusive.

All persons other than defendants who acquired Agilon securities, including purchasers of common stock, publicly traded on the NYSE during the Class Period, and who were damaged thereby. All such investors may be eligible to join the Agilon Health, Inc. (AGL) class action lawsuit.

Allegations in the Agilon Health, Inc. (AGL) Securities Class Action Lawsuit

The lawsuit names Agilon Health, Inc., Chief Executive Officer Steven Sell, and Chief Financial Officer Jeffrey Schwaneke, for alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act and Rule 10b-5. According to the complaint, defendants told investors that Agilon's "strategic actions" reduced risk through risk management initiatives and would positively affect 2025 results, while maintaining guidance despite a challenging Medicare Advantage environment, including higher-than-expected utilization trends among MA patients, and that their risk disclosures in SEC filings characterized materialized risks as mere possibilities.

The story begins on February 25, 2025, when Agilon issued a press release setting full-year 2025 guidance that "reflects the positive impact from strategic actions and assumes continued elevated medical cost trends," driven by increased Medicare Advantage patient utilization, and stated the "Class of 2025" was expected to add about 20,000 Medicare Advantage members. That same day, CEO Steven Sell said the Company had "established a stronger foundation for success" through actions to reduce underwriting risks, improve platform capabilities, and maintain cost discipline, touting visibility into utilization trends, framing these steps as drivers of "long-term sustainable financial performance." As the year unfolded, on May 5, 2025, Sell told investors on the first quarter call that Agilon was "on track to deliver in line with our full year 2025 guidance," reaffirming revenue estimates and financial projections.

Meanwhile, the complaint alleges that defendants knew or should have known that industry headwinds were more acute than described and that the immediate financial benefits from the Company's strategic actions, overstating the business model's effectiveness and the strategic actions' impact, were misrepresented. Investors allege the 2025 guidance lacked a reasonable basis, was unattainable, and statements about being "on track" concealed that expected improvements would not be realized in 2025, while reserves for medical costs were understated and proved inadequate.

The Truth Emerges

The picture shifted on August 4, 2025. In a press release, Agilon announced disappointing financial results, suspended its 2025 (financial guidance), and disclosed that CEO Steven Sell had stepped down. Management acknowledged that "the industry headwinds are more acute than previously expected," and that enhanced data showed 2024 and 2025 risk adjustment was "lower than previously expected," affecting near-term results and revealing less visibility into utilization trends than previously represented.

On the Q2 2025 earnings call later that day, Executive Chairman Ronald Williams revealed that actions taken in 2024 would not deliver the anticipated positive impact until 2026. He stated, "Given the long-term nature of our business cycle, we have not yet captured the full upside from these enhancements this year, but are confident in realizing them in 2026," and conceded that execution "was not adequate." These admissions contradicted prior assurances that 2025 guidance was sound and that strategic actions were already driving 2025 performance, undercutting prior claims that risk had been reduced, and the guidance suspension implicitly acknowledged prior inaccuracy.

Market Reaction

After the August 4, 2025 after-hours call, the market reacted sharply to the corrective disclosures the next trading day. On August 5, 2025, Agilon's stock fell $0.9349 per share, or 51.50%, to close at $0.8801, leaving shareholders with significant investment losses. The complaint ties this sudden drop to the suspension of guidance, the CEO's departure, and management's acknowledgment that expected benefits would be delayed and headwinds were worse than previously represented, as the market learned the truth about agilon's near-term outlook.

Next Steps

● The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.

● The Court will then consider motion for class certification.

● The Court will later consider a Motion to Dismiss.

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.

Check Eligibility

✓ Free case evaluation
✓ No cost or obligation
✓ See if you qualify

First Name *

Last Name *

Email *

Phone

Estimated Loss

Number of Shares

Purchase Date

Full Name

Submitting this form does not create an attorney-client relationship. Your information is confidential.

Or contact us directly:

(212) 363-7500 [email protected]

Never Miss Another Deadline

Choose your preferred way to stay informed of new case launches and settlement deadlines.

Scan the QR code or click the button to join.

Join on WhatsApp

First Name *

Last Name *

Email *

Full Name

Submitting this form does not create an attorney-client relationship. Your information is confidential.

[email protected] (212) 363-7500

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

I have reviewed a complaint filed in the action.
I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
My transaction(s) in agilon health, inc. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
Within the last 3 years,
I have not sought to serve nor have I served as a class representative in any federal securities fraud case. I have sought to serve as a class representative in
I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Yes. I certify under penalty of perjury that the foregoing is true and correct. Executed this No. I certify under penalty of perjury under the laws of the United States of America that the foregoing is true and correct. Executed this

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against agilon health, inc. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

I have reviewed the complaint linked in paragraph 1